Biotechnology News XALATAN Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-6 out of 6 found

Current Search: xalatan: 6

Pfizer Earnings Call, First Quarter 2008
The pharmaceutical company reported net income of $2.8 billion or 41 cents a share, down 18% from $3.4 billion or 48 cents a share from the prior year due to lower revenues due to the U.S.

losses of exclusivity discussed above and...

123Jump: Jun 5 2008 9:27AM
Matching: xalatan

Find similar documents

Experimental drug cuts eye pressure: NicOx
NicOx S.A.

announced the results of a US phase II study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan (latanoprost) 0.005 per cent in patients with primary...

PharmaBiz: May 8 2008 8:19AM
Matching: xalatan

Find similar documents

NicOx reports encouraging results from Phase IIa glaucoma trial
demonstrated a clinically significant reduction in diurnal intraocular pressure (IOP) from baseline and the highest dose showed consistently more IOP lowering than Xalatan 0.005%, at all study visits and at all individual time points,...

Pharmaceutical Business Review: May 8 2008 8:35AM
Matching: xalatan

Find similar documents

Pfizer drops glaucoma drug, NicOx shares slump
Drug & Device Development PARIS (Reuters) - Pfizer Inc has decided not to take NicOx SA's experimental glaucoma drug PF-03187207 into final phase III tests after a mid-stage study failed to meet its primary endpoint, sending NicOx...

Reuters Health: May 7 2008 1:50AM
Matching: xalatan

Find similar documents

Nicox says Pfizer not to launch phase 3 study for PF-03187207
PARIS (Thomson Financial) - Nicox said Pfizer Inc.

has decided not to launch a phase 3 study for the PF-03187207 drug under the companies' joint research programme.

'Nevertheless, Pfizer has reaffirmed its commitment to the ongoing joint...

Sharewatch: May 6 2008 5:57AM
Matching: xalatan

Find similar documents

Biovitrum Presents Detailed Results from Clinical Neuropathic Pain and Glaucoma Projects
Biovitrum invites press and analysts to a meeting on May 7th from 3 - 5 p.m.

(CET) at SwedenBio, Wallingatan 24, Stockholm, Sweden.

STOCKHOLM, April 29, 2008-We have recently completed two patient studies with new unique treatments.

Pharma Live: Apr 29 2008 12:33PM
Matching: xalatan

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.